dc.contributor.author |
Hafsteinsdóttir, Brynhildur |
dc.contributor.author |
Dalemo, Ellen |
dc.contributor.author |
Elíasdóttir, Ólöf |
dc.contributor.author |
Ólafsson, Elías |
dc.contributor.author |
Axelsson, Markus |
dc.date.accessioned |
2023-04-29T01:03:19Z |
dc.date.available |
2023-04-29T01:03:19Z |
dc.date.issued |
2023-03 |
dc.identifier.citation |
Hafsteinsdóttir , B , Dalemo , E , Elíasdóttir , Ó , Ólafsson , E & Axelsson , M 2023 , ' Decreased incidence of Guillain-Barré syndrome during the COVID-19 pandemic : a retrospective population-based study ' , Neuroepidemiology , vol. 57 , no. 1 , pp. 1-6 . https://doi.org/10.1159/000527726 |
dc.identifier.issn |
0251-5350 |
dc.identifier.other |
70683591 |
dc.identifier.other |
0d99e9d4-7cef-4c86-8d07-6a03b4a90cd1 |
dc.identifier.other |
36366822 |
dc.identifier.other |
85144516695 |
dc.identifier.other |
unpaywall: 10.1159/000527726 |
dc.identifier.uri |
https://hdl.handle.net/20.500.11815/4182 |
dc.description |
The Author(s). Published by S. Karger AG, Basel. |
dc.description.abstract |
Background: Guillain-Barré syndrome is an immune-mediated acute inflammatory polyneuropathy that is associated with various triggers, including certain infections and vaccines. It has been suggested that both SARS-CoV-2 infection and vaccination may be triggering factors for Guillain-Barré syndrome, but evidence remains equivocal. Here, we conducted a population-based incidence study of Guillain-Barré syndrome spanning the 3 years immediately prior to and the 2 years during the pandemic. Methods: Cases were identified by searching a regional diagnostic database for the ICD-10 code for Guillain-Barré syndrome. Individuals who fulfilled the Brighton criteria for Guillain-Barré syndrome were included. Information on clinical presentation, laboratory values, and vaccination status were retrieved from medical records. We calculated the incidence immediately prior to and during the pandemic. Results: The Guillain-Barré syndrome incidence rate was 1.35/100,000 person-years for the pre-pandemic period and 0.66/100,000 person-years for the pandemic period (incidence rate ratio: 0.49; p = 0.003). Three cases were temporally associated with SARS-CoV-2 infection and 1 case each to the AstraZeneca and Pfizer-BioNTech COVID-19 vaccines. Conclusions: Our results show that the incidence of Guillain-Barré syndrome decreased during the pandemic. This is most likely due to decreased prevalence of triggering infections due to social restrictions. Our findings do not support a causal relationship between Guillain-Barré syndrome and COVID-19. |
dc.format.extent |
6 |
dc.format.extent |
132773 |
dc.format.extent |
1-6 |
dc.language.iso |
en |
dc.relation.ispartofseries |
Neuroepidemiology; 57(1) |
dc.rights |
info:eu-repo/semantics/openAccess |
dc.subject |
Taugasjúkdómafræði |
dc.subject |
COVID-19 |
dc.subject |
Guillain-Barr syndrome |
dc.subject |
Incidence |
dc.subject |
Population-based studies |
dc.subject |
Vaccine |
dc.subject |
Pandemics |
dc.subject |
Humans |
dc.subject |
SARS-CoV-2 |
dc.subject |
COVID-19/epidemiology |
dc.subject |
COVID-19 Vaccines |
dc.subject |
Guillain-Barre Syndrome/epidemiology |
dc.subject |
Influenza Vaccines |
dc.subject |
Retrospective Studies |
dc.subject |
Neurology (clinical) |
dc.subject |
Epidemiology |
dc.title |
Decreased incidence of Guillain-Barré syndrome during the COVID-19 pandemic : a retrospective population-based study |
dc.type |
/dk/atira/pure/researchoutput/researchoutputtypes/contributiontojournal/article |
dc.description.version |
Peer reviewed |
dc.identifier.doi |
10.1159/000527726 |
dc.relation.url |
http://www.scopus.com/inward/record.url?scp=85144516695&partnerID=8YFLogxK |
dc.contributor.department |
Faculty of Medicine |
dc.contributor.department |
Internal Medicine and Emergency Services |